SeQure Dx, a gene-editing diagnostics company, announced today a $17.5 million Series A funding led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments. Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.
(以上内容由医药魔方AI生成)
